Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    YM BIOSCIENCES INC.
    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars, unless otherwise indicated)

    ---------------------------------------
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)...   Ceres, Inc . (Nasdaq: CERE ... financial results for the three months ended May 31, ... Ceres reported that the company and its customers ... season in Brazil, which concluded in June, despite dry ... areas for part of the growing season. Yields of ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... are today,s highlights from the AACE Annual Meeting & Clinical Congress in Boston : ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b ) , ... Research Shows First-of-Its-Kind Hydrogel Decreases Obese Patients, Desire for Food   , ... New research indicates that a first-of-its-kind, superabsorbent hydrogel significantly increased the post-meal ...
... NEW YORK and SCOTTSDALE, Ariz. , ... Amex: NBS ), an international biopharmaceutical,company with operations ... BioSciences,Inc., a wholly owned subsidiary of IR BioSciences Holdings, ... entered into a,Collaborative Research Agreement, focused on the development ...
... ... Biotechnology Companies , ... Rochester, New York (PRWEB) April 22, 2010 -- iCardiac Technologies, Inc., a provider of ... has awarded iCardiac a cardiac safety study leveraging iCardiac’s COMPAS technology platform including advanced ...
Cached Biology Technology:Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress 2Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress 3NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 2NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 3NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 4NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 5NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 6NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 7Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:7/11/2014)... The University of Chicago is creating a new ... at the University,s Institute for Molecular Engineering and ... million donation from the Millicent and Eugene Bell ... will reside within the Institute for Molecular Engineering. ... research project at the MBL,s Eugene Bell Center ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... July 11, 2014 The increased risk of kidney ... in resuscitation fluids reflects the mass of HES molecules, ... , official journal of the International Anesthesia Research Society ... the harmful effect of HES on cultured human renal ... Dr Christian Wunder and colleagues of University Hospital Wrzburg, ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... The first analysis of the healthful antioxidant content ... South America concludes that some of these fruits have ... renowned as "super fruits" sold throughout the United ... protection against heart disease, cancer and other conditions, the ...
... not rely on oxygen may have played an important role ... a theory that UChicago researcher Albert Colman is testing in ... He has found that bacteria at the site produce ... scientists must take into account as they attempt to reconstruct ...
... Planes were grounded all over Europe when the Eyjafjallajkull volcano erupted ... fly zone was really necessary. And the only way to find ... cloud - a potentially fatal experiment. , Now a team ... Iceland have developed a protocol for rapidly providing air traffic authorities ...
Cached Biology News:Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3Novel ash analysis validates volcano no-fly zones 2
...
...
... Anti-β-Tubulin IV Recognizes an epitope ... of β-tubulin isotype IV. No ... is observed. ascites fluid synthetic ... sequence of β-tubulin isotype IV, ...
... Finnpipette BioControl is a major step ... complete liquid handling system - with ... tip cone modules. All five single ... modules fit one handle. The lightweight ...
Biology Products: